Thierry Andre, MD, a professor of medical oncology at the University Pierre et Marie Curie, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses factors that a community oncologist should consider when choosing the right treatment for patients with metastatic colorectal cancer.
Thierry Andre, MD, a professor of medical oncology at the University Pierre et Marie Curie, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses factors that a community oncologist should consider when choosing the right treatment for patients with metastatic colorectal cancer.
To date, the best way to treat patients with colorectal or metastatic colorectal cancer is with radiation. This is the standard of care for all gastric cancers at the St. Antoine Hospital in Paris, Andre explains.
Despite the success in the field of immunotherapies, every patient needs to be looked at individually before coming up with a treatment regimen. Immunotherapies should only be used on patients that can expect to benefit from this treatment.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More